Detalhe da pesquisa
1.
A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Ann Oncol
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729567